Physician profile
Slava I Kulakov
NPI 1073524104
$836.09
in general payments reported to CMS, 2019-2025
10 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $125 · 2021: $18.81 · 2022: $63.85 · 2023: $181 · 2024: $154 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $250.00 | 2024-2025 | Breztri, Airsupra |
| Pfizer INC. | $174.90 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.05 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $130.26 | 2019 | |
| Sumitomo Pharma America, INC. | $41.34 | 2023 | Gemtesa |
| Abbvie INC. | $27.79 | 2022-2024 | |
| Novo Nordisk INC | $22.48 | 2019 | |
| Glaxosmithkline, LLC. | $18.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.48 | 2025 | Jardiance |
| Ardelyx, INC. | $14.98 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Slava Kulakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.